Schizophrenia

On Monday, AbbVie Inc (NYSE:ABBV) stock is trading lower after it released data from its two Phase 2 EMPOWER trials of emraclidine for schizophrenia. The trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia. The patients experienced an...

Last week, the FDA approved Bristol Myers Squibb & Co’s (NYSE:BMY) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. Analysts at investment bank EF Hutton says, “This bodes well for Reviva’s Brilaroxazine, a...

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With...

The FDA has approved a clinical trial that will assess PharmAla Biotech Holdings' (OTC: PMBHF) proprietary LaNeo Investigational Medical Product (IMP) 40mg MDMA capsules for the treatment of schizophrenia. This is the first time these capsules will be tried on humans in the U.S...

This article was originally published on Psychedelic Spotlight and appears here with permission. Psychedelics and schizophrenia share a history. Now, researchers are looking at how psychedelics may change the future. Can psychedelics help treat schizophrenia? LSD-25 sat on a shelf for five years...

Several recent studies have found a link between cannabis use and mental conditions such as psychosis and schizophrenia. A study published in the World Journal of Biological Psychiatry suggested that marijuana use increases the risk for a myriad of conditions ranging from transient psychotic states...

Addex Therapeutics (NASDAQ: ADXN) has moved a selective and potent M4 muscarinic receptor positive allosteric modulator (PAM) program into lead optimization, with a potential treatment of schizophrenia and other neuropsychiatric disorders. Using its proprietary allosteric modulator...

According to an SEC filing, Karuna Therapeutics Inc (NASDAQ: KRTX) is withdrawing its prior guidance for the timing of topline data for its Phase 3 EMERGENT-3 trial evaluating KarXT in schizophrenia.  The Company had expected topline data from the EMERGENT-3 trial in 2H of 2022. At...

This article was originally published on The Fresh Toast and appears here with permission. New study finds link between cannabis use in teens and schizophrenia, regardless of how often they’re consuming. Cannabis and teen drug use are topics that have long concerned us. While there’s a...

Alkermes plc's (NASDAQ: ALKS) ENLIGHTEN-Early Phase 3b study of Lybalvi (olanzapine & samidorphan) met its prespecified primary endpoint on body weight in young schizophrenia adult patients in the early stage of the disease.  Patients treated with Lybalvi experienced...

The FDA has notified Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) that it may proceed with Phase 3 trial of its lead candidate, brilaroxazine, a serotonin and dopamine receptor modulator for schizophrenia. The FDA has also signed off an additional Phase 3 trial focused on...

The FDA has extended the review period for BioXcel Therapeutics Inc's (NASDAQ: BTAI) marketing application seeking approval for BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II. In connection with the FDA's...

Neurocrine Biosciences Inc (NASDAQ: NBIX) has outlined a deal that provides Sosei Heptares Corporation $100 million upfront, R&D expenses, and a motherlode of milestones worth up to $2.6 billion if successful.  Under the terms of the agreement, Neurocrine...

ATAI Life Sciences NV (NASDAQ: ATAI) announced interim data from the first 8-patient cohort of its Phase 2a trial of RL-007 for Cognitive Impairment Associated with Schizophrenia (CIAS). Related Link: Peter Thiel Backed Atai Life Launches New Mental Health Disorders-Focused...

Teva Pharmaceuticals Industries Ltd (NYSE: TEVA) announced results from the Phase 3 trial comparing TV-46000/mdc-IRM once monthly (q1m) and TV-46000/mdc-IRM once every two months (q2m) with placebo for schizophrenia patients who underwent stabilization on oral risperidone. ...